Research Site

Pouso Alegre 37554-216

1 studies enrolling now · 3 studies all time

What they study most

Breast Cancer, Early Breast Cancer, Ophthalmic Safety in Patients With Breast Cancer

Studies at this site

• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• An Ophthalmic Safety Study in Patients With Breast Cancer — Running, not enrolling